TriSalus Life Sciences, Inc. (NASDAQ:TLSI) CEO Mary T. Szela Buys 4,826 Shares

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) CEO Mary T. Szela purchased 4,826 shares of TriSalus Life Sciences stock in a transaction that occurred on Monday, January 27th. The stock was bought at an average cost of $5.42 per share, for a total transaction of $26,156.92. Following the purchase, the chief executive officer now directly owns 429,503 shares in the company, valued at $2,327,906.26. This trade represents a 1.14 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

TriSalus Life Sciences Stock Performance

Shares of TLSI opened at $4.93 on Thursday. The business’s 50-day moving average is $4.55 and its two-hundred day moving average is $4.75. The company has a market capitalization of $150.32 million, a P/E ratio of -1.98 and a beta of 0.51. TriSalus Life Sciences, Inc. has a fifty-two week low of $3.50 and a fifty-two week high of $10.42.

Institutional Trading of TriSalus Life Sciences

Several hedge funds and other institutional investors have recently bought and sold shares of TLSI. Walleye Capital LLC acquired a new position in TriSalus Life Sciences in the third quarter valued at approximately $66,000. Virtu Financial LLC purchased a new position in shares of TriSalus Life Sciences during the 3rd quarter valued at approximately $92,000. Vestcor Inc acquired a new position in shares of TriSalus Life Sciences in the 3rd quarter valued at $108,000. MSD Partners L.P. purchased a new stake in TriSalus Life Sciences during the third quarter worth $184,000. Finally, Geode Capital Management LLC grew its position in TriSalus Life Sciences by 45.4% during the third quarter. Geode Capital Management LLC now owns 200,427 shares of the company’s stock valued at $924,000 after buying an additional 62,542 shares during the period. 2.58% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on TLSI shares. Roth Capital raised TriSalus Life Sciences to a “strong-buy” rating in a research note on Monday, November 11th. Canaccord Genuity Group reduced their price objective on shares of TriSalus Life Sciences from $12.00 to $11.00 and set a “buy” rating for the company in a research note on Friday, November 15th. Northland Securities began coverage on TriSalus Life Sciences in a research note on Friday, October 25th. They set an “outperform” rating and a $12.50 price target on the stock. Cantor Fitzgerald began coverage on TriSalus Life Sciences in a research report on Tuesday, December 17th. They issued an “overweight” rating and a $10.00 target price on the stock. Finally, Roth Mkm reiterated a “buy” rating and set a $11.00 price target on shares of TriSalus Life Sciences in a research note on Friday, January 24th. Seven investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $11.79.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.